WHO ML3 Status and ICH Membership: What They Mean for Devices

1. Key takeaways

In the second half of 2025 Nigeria recorded two high-profile international credential events:

• On 12 August 2025, NAFDAC officially announced that NAFDAC–PCN had retained WHO Maturity Level 3 (ML3) status, with the scope defined as the Regulation of Medicines and Vaccines;
• On 18–19 November 2025, at the ICH Assembly in Singapore, NAFDAC became the 24th member of ICH (ICH press release of 26 November 2025; 25 members and 41 observers in total).

The correct reading for device companies is this: both events show that NAFDAC’s regulatory system capability is improving, but neither can be stretched into device mutual recognition or a device reliance channel. The improvement is real and worth acknowledging; the temptation to convert it into a marketing shortcut is where the risk begins.

2. Legal basis

3. Expert insights

Insight 1: the official ML3 wording carries a scope qualifier — medicines and vaccines.

The title and body of the NAFDAC press release expressly limit the achievement to the Regulation of Medicines and Vaccines. WHO maturity levels are themselves assessed separately by functional domain (medicines, vaccines, devices and so on), and a rating earned in one domain is not transferable to another. Therefore any statement that NAFDAC holds ML3 must carry the scope; omitting the scope is a distortion. No WHO maturity level assessment for the device domain in Nigeria has been announced.

Insight 2: ICH covers medicines and does not cover devices.

ICH (the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) harmonizes quality, safety, efficacy and multidisciplinary topics for medicines, and does not address medical devices. NAFDAC’s ICH membership is a signal that the medicines regulatory system is aligning with international practice; it has no direct regulatory connection to the device registration pathway.

Insight 3: nevertheless, both credentials do have an indirect entry point in the reliance directive.

Section 2.1.1 of NAFDAC-RDRR-005-04 lists WLA/VICH/ICH observer authorities among the acceptable reliance sources. Note the direction: this is a qualification assessment of other authorities, not an assessment of NAFDAC itself — the direction is opposite. In other words, ICH membership may help NAFDAC judge whether a foreign authority is credible, but it will not make foreign authorities automatically accept NAFDAC.

Insight 4: why this red line matters — because it directly affects commercial judgment.

If a team wrongly assumes that NAFDAC’s ML3 status or ICH membership allows devices to ride a mutual recognition fast track, the result is distorted project schedules, quotations and commitments. Article 42 has already established that reliance is non-mutual (§3.1.4) and that NAFDAC retains the national decision right (§3.1.5). Together these three points form the statement boundary that must be defended in all Nigerian compliance communication.

Insight 5: the correct use is capability endorsement, not pathway commitment.

The legitimate use of ML3 status and ICH membership is to explain to management and partners that the maturity and review discipline of the Nigerian regulatory system are improving, thereby supporting long-term investment decisions. A market whose authority retains ML3 and joins ICH is a market whose institutions are strengthening, and that is a fair ground for patience with market entry. Do not write them into turnaround commitments given to customers or compliance declarations in tender documents.

4. Practical recommendations

1. Whenever ML3 is cited, always carry the scope qualifier of medicines and vaccines; never omit it and never generalize it.
2. Whenever ICH membership is cited, state that its scope is medicines and do not link it to device registration.
3. Never describe either credential as device mutual recognition or a device fast track in external documents.
4. Anchor reliance claims back to the nine categories under §2.1 and Regulation 14, and argue case by case.
5. Use the two credentials for internal capability assessment and long-term decisions, not for turnaround commitments.
6. Keep monitoring whether WHO adds a device-domain maturity level assessment for NAFDAC; once published it would be a major positive signal.

5. Verification checklist

• □ ML3 citations carry the medicines and vaccines scope (12 August 2025).
• □ ICH membership citations state the medicines scope (November 2025).
• □ External documents contain no device mutual recognition or device fast track wording.
• □ Reliance claims are argued through the nine categories of §2.1 and Regulation 14.
• □ The two credentials have not been written into turnaround commitments or tender compliance declarations.
• □ A monitoring mechanism for a WHO device-domain maturity level assessment has been set up.

Regulatory information verified as of 29 October 2026. The facts cited in this document come from the NAFDAC official press release (12 August 2025, ML3 retained, scope: regulation of medicines and vaccines) and the ICH Assembly and press release (Assembly 18–19 November 2025; press release 26 November 2025, 25 members and 41 observers); the reliance boundary has been checked against NAFDAC-RDRR-005-04 (§2.1.1, §3.1.4, §3.1.5) and S.I. No. 42 of 2024, Regulation 14. Neither credential constitutes device mutual recognition.

• Local Nigeria resources: GRZAN can coordinate locally licensed import entities and authorized representative resources, covering NAPAMS online submission, dossier screening clearance interfacing, import permits, sample delivery and laboratory analysis support.
• Service capability: classification determination, registration pathway selection, technical documentation (IMDRF ToC) drafting, CMFS and notarization/legalization, GMP and foreign inspection preparation, advertisement permits, vigilance and PMS reporting, change management and renewal.
• Contact: info@grzanglobal.com; website www.grzan.cn.